VJHemOnc is committed to improving our service to you

EHA 2019 | Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd

VJHemOnc is committed to improving our service to you

Philippe Moreau

Philippe Moreau, University Hospital, Nantes, France, presents the results of part 1 of the CASSIOPEIA trial (NCT02541383). This trial investigated bortezomib, thalidomide, dexamethasone (VTD) followed by stem cell transplantation, followed by two cycles of consolidation therapy with VTD with or without daratumumab in newly diagnosed multiple myeloma. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter